Liver Pathobiology: insights through the lens of rare diseases
肝脏病理学:从罕见疾病的角度洞察
基本信息
- 批准号:10636874
- 负责人:
- 金额:$ 49.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAscitesCapillarityCause of DeathCell SeparationCellsCessation of lifeCirrhosisClinicalCuesEndothelial CellsEsophagusEtiologyEventFutureGenotypeGoalsHemorrhageHepaticHepatic EncephalopathyHumanIndividualKnowledgeLeadLiverLiver DysfunctionLiver FibrosisLiver diseasesMedicalMolecularMonomeric GTP-Binding ProteinsMusNamesOrgan DonorPathogenesisPathologyPersonsPhenotypePortal HypertensionRare DiseasesResearchSignal TransductionSignal Transduction PathwaySortingTherapeuticcell dedifferentiationchronic liver diseasechronic liver injuryclinically significantcommon treatmentcurative treatmentsend stage liver diseaseglobal healthinsightlensliver injuryliver transplantationloss of functionmortalitymutant mouse modelnew therapeutic targetnovelnovel diagnosticspreventprognosticsingle-cell RNA sequencingtool
项目摘要
PROJECT SUMMARY/ABSTRACT
Chronic liver disease (CLD) is a major global health problem that affects over 1 billion people globally and leads
up to 2 million deaths annually. Chronic liver injury is typically silent, but when persistent may lead to liver fibrosis,
which can progress to cirrhosis and clinically significant portal hypertension complications (such as ascites,
esophageal variceal hemorrhage, and hepatic encephalopathy). These clinical signs are the most common
cause of mortality from CLD, and for which liver transplantation is the only available curative intervention. Since
the demands for liver transplantation still far exceeds the supply of available donor organs, end-stage liver
disease represents the 11th leading cause of death worldwide. Hence, advances in the molecular understanding
of liver injury and pathobiology are critical to develop novel diagnostic, prognostic and therapeutic tools, with the
goal to decrease the demand for liver transplantation in the future. For several years, my research has focused
on the study of individuals with rare liver phenotypes of unknown etiology as a roadmap to uncover novel
molecular mechanism(s) underlying liver pathology that may be relevant to the pathogenesis and treatment of
common liver diseases. As part of this ongoing effort, we recently found that recessive genotypes in a small
GTPase, named GIMAP5, cause liver sinusoidal endothelial cell capillarization and liver dysfunction. Taking
advantage of an available Gimap5 loss-of-function (LOF) mutant mouse model, which recapitulates the
sinusoidal endothelial cell capillarization phenotype seen in Gimap5-deficient humans, we demonstrate that
Gimap5 is expressed in liver endothelial cells and its selective deletion in these cells lead to liver sinusoidal
endothelial cell (LSEC) de-differentiation into capillarized endothelial cells (CECs). Furthermore, single cell RNA-
sequencing analysis of sorted liver endothelial cells isolated from Gimap5-deficient and Gimap5-sufficient mice
shows a near complete replacement of healthy LSECs by CECs. Importantly, LSEC de-differentiation into CECs
is an event described in liver fibrosis, in general, independent of the etiology of liver injury. Here, we propose to
define the key contributors in maintaining LSEC identity and preventing hepatic sinusoidal endothelial cell
capillarization through the completion of the following two aims: (1) identify the cell extrinsic cues that signal
through GIMAP5 to maintain LSEC identity; and (2) characterize the Gimap5 signal transduction pathway in liver
endothelial cells. Collectively, the knowledge generated by this proposal has the potential to identify novel
therapeutic targets to revert CECs into healthy LSECs, and this way develop new non-invasive therapies for liver
fibrosis, cirrhosis and portal hypertension, which represent a major unmet medical need.
项目总结/摘要
慢性肝病(CLD)是一个主要的全球健康问题,影响全球超过10亿人,
每年有200万人死亡。慢性肝损伤通常是无症状的,但持续存在时可能会导致肝纤维化,
其可发展为肝硬化和临床上显著的门静脉高压并发症(如腹水,
食管静脉曲张出血和肝性脑病)。这些临床症状是最常见的
CLD的死亡原因,肝移植是唯一可用的治疗干预。以来
对肝移植的需求仍然远远超过可用供体器官的供应,
疾病是全球第11大死亡原因。因此,分子理解的进步
肝损伤和病理生物学的研究对于开发新的诊断、预后和治疗工具至关重要,
目的是减少未来肝移植的需求。几年来,我的研究集中在
研究病因不明的罕见肝脏表型个体,作为发现新的
可能与以下疾病的发病机制和治疗相关的肝脏病理学的分子机制
常见的肝脏疾病作为这项持续努力的一部分,我们最近发现,在一个小的隐性基因型,
GT3,命名为GIMAP 5,引起肝窦内皮细胞毛细血管化和肝功能障碍。以
一个可用的Gimap 5功能丧失(LOF)突变小鼠模型的优点,它概括了
我们证明,在Gimap 5缺陷型人类中观察到的窦内皮细胞毛细血管化表型
Gimap 5在肝内皮细胞中表达,其在这些细胞中的选择性缺失导致肝窦状隙
内皮细胞(LSEC)去分化为毛细血管化内皮细胞(CEC)。此外,单细胞RNA-
从Gimap 5缺陷和Gimap 5充足小鼠分离的分选的肝内皮细胞的测序分析
显示CEC几乎完全取代健康的LSEC。重要的是,LSEC去分化为CEC
是肝纤维化中描述的一种事件,通常与肝损伤的病因无关。在此,我们建议
确定维持LSEC身份和防止肝窦内皮细胞
通过完成以下两个目标来实现毛细作用:(1)识别发出信号的细胞外部线索
通过GIMAP 5来维持LSEC身份;和(2)表征肝脏中的Gimap 5信号转导途径
内皮细胞总的来说,这项提议产生的知识有可能发现新的
治疗目标是将CEC恢复为健康的LSEC,并以这种方式开发新的非侵入性肝脏治疗方法
肝纤维化、肝硬化和门静脉高压,这代表了一个主要的未满足的医疗需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Silvia Vilarinho其他文献
Silvia Vilarinho的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Silvia Vilarinho', 18)}}的其他基金
Deciphering the Genetic Basis of Portal Hypertension
破译门脉高压的遗传基础
- 批准号:
9917767 - 财政年份:2018
- 资助金额:
$ 49.17万 - 项目类别:
Deciphering the Genetic Basis of Portal Hypertension
破译门脉高压的遗传基础
- 批准号:
10398119 - 财政年份:2018
- 资助金额:
$ 49.17万 - 项目类别:
相似海外基金
Analyses of immune response and bacteria in cirrhotic ascites with Tm mapping method.
Tm 图谱法分析肝硬化腹水中的免疫反应和细菌。
- 批准号:
20K08305 - 财政年份:2020
- 资助金额:
$ 49.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Randomized controlled trial to elucidate "would patients be weakened if ascites removed?"
随机对照试验阐明“如果腹水被清除,患者会变得虚弱吗?”
- 批准号:
20K16567 - 财政年份:2020
- 资助金额:
$ 49.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of new immuno-cell therapy for the treatment of refractory malignant ascites and pleural effusion
开发新的免疫细胞疗法治疗难治性恶性腹水和胸腔积液
- 批准号:
19K09196 - 财政年份:2019
- 资助金额:
$ 49.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Ascites proteomics reveal the mechanism of pancreatic cancer peritoneal dissemination
腹水蛋白质组学揭示胰腺癌腹膜播散机制
- 批准号:
19K18107 - 财政年份:2019
- 资助金额:
$ 49.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A Novel Therapy for gastrointestinal cancer targeting exosome in malignant ascites
一种针对恶性腹水中外泌体的胃肠癌新疗法
- 批准号:
18H02882 - 财政年份:2018
- 资助金额:
$ 49.17万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Peritoneal metastasis Prediction by exosome in washing ascites for gastric cancer
胃癌洗腹水中外泌体预测腹膜转移
- 批准号:
18K16321 - 财政年份:2018
- 资助金额:
$ 49.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Label-free microfluidic enrichment of cancer cells from noncancer cells in ascites fluid
无标记微流体从腹水中的非癌细胞中富集癌细胞
- 批准号:
9251748 - 财政年份:2016
- 资助金额:
$ 49.17万 - 项目类别:
Preparation of ascites purification device for cancerous ascites and establishment of portable continuous ascites purification perfusion method
癌性腹水腹水净化装置的研制及便携式连续腹水净化灌注方法的建立
- 批准号:
16K01425 - 财政年份:2016
- 资助金额:
$ 49.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Label-free microfluidic enrichment of cancer cells from noncancer cells in ascites fluid
无标记微流体从腹水中的非癌细胞中富集癌细胞
- 批准号:
9036692 - 财政年份:2016
- 资助金额:
$ 49.17万 - 项目类别:
Identifying Factors in Malignant Ascites Facilitating Gastric Adenocarcinoma Peritoneal Metastasis
确定恶性腹水促进胃腺癌腹膜转移的因素
- 批准号:
349961 - 财政年份:2015
- 资助金额:
$ 49.17万 - 项目类别:
Studentship Programs